1 nducted to investigate the longevity of this antiadrenergic action after adenosine exposure.

2 le, sotalol and amiodarone, also have potent antiadrenergic actions.

3 large patient sample treated with a powerful antiadrenergic agent.

4             The magnitude of this persistent antiadrenergic effect (PAE) of adenosine at 15 minutes o

5 how that CST can exert anti-inflammatory and antiadrenergic effects by suppressing the inflammatory a

6 (w)-nitro-L-arginine methyl ester eliminated antiadrenergic effects of SIL, yet this was not restorab

7                                   Drugs with antiadrenergic effects reduce POAF.

8 fficacy appears to be related importantly to antiadrenergic effects, the mechanism for which has not

9 nt, and L-type calcium current, and exhibits antiadrenergic effects.

10 r restored PDE5A z-band localization and the antiadrenergic efficacy of PDE5A inhibition.

11 gement includes pharmacological and surgical antiadrenergic interventions with sodium channel blocker

12                                          The antiadrenergic potential of NTG was investigated by exam

13 ial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.

14 2 may, thus, represent a novel intracellular antiadrenergic therapeutic strategy protecting the heart

15 iopathic dilated or ischemic cardiomyopathy, antiadrenergic therapy with beta-blocking agents appears

16  Importantly, there is ample room to improve antiadrenergic therapy, through novel approaches exploit

17  a worse prognosis, and predicts response to antiadrenergic therapy.